These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 10762498)

  • 1. AMPA receptor blockade improves levodopa-induced dyskinesia in MPTP monkeys.
    Konitsiotis S; Blanchet PJ; Verhagen L; Lamers E; Chase TN
    Neurology; 2000 Apr; 54(8):1589-95. PubMed ID: 10762498
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined blockade of AMPA and NMDA glutamate receptors reduces levodopa-induced motor complications in animal models of PD.
    Bibbiani F; Oh JD; Kielaite A; Collins MA; Smith C; Chase TN
    Exp Neurol; 2005 Dec; 196(2):422-9. PubMed ID: 16203001
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differing effects of N-methyl-D-aspartate receptor subtype selective antagonists on dyskinesias in levodopa-treated 1-methyl-4-phenyl-tetrahydropyridine monkeys.
    Blanchet PJ; Konitsiotis S; Whittemore ER; Zhou ZL; Woodward RM; Chase TN
    J Pharmacol Exp Ther; 1999 Sep; 290(3):1034-40. PubMed ID: 10454475
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Changes in glutamate receptors in dyskinetic parkinsonian monkeys after unilateral subthalamotomy.
    Jourdain VA; Morin N; Grégoire L; Morissette M; Di Paolo T
    J Neurosurg; 2015 Dec; 123(6):1383-93. PubMed ID: 25932606
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Levodopa-induced dyskinesias improved by a glutamate antagonist in Parkinsonian monkeys.
    Papa SM; Chase TN
    Ann Neurol; 1996 May; 39(5):574-8. PubMed ID: 8619541
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changes of AMPA receptors in MPTP monkeys with levodopa-induced dyskinesias.
    Ouattara B; Hoyer D; Grégoire L; Morissette M; Gasparini F; Gomez-Mancilla B; Di Paolo T
    Neuroscience; 2010 Jun; 167(4):1160-7. PubMed ID: 20303391
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MPEP, an mGlu5 receptor antagonist, reduces the development of L-DOPA-induced motor complications in de novo parkinsonian monkeys: biochemical correlates.
    Morin N; Grégoire L; Morissette M; Desrayaud S; Gomez-Mancilla B; Gasparini F; Di Paolo T
    Neuropharmacology; 2013 Mar; 66():355-64. PubMed ID: 22884464
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevention of dyskinesia by an NMDA receptor antagonist in MPTP monkeys: effect on adenosine A2A receptors.
    Morissette M; Dridi M; Calon F; Hadj Tahar A; Meltzer LT; Bédard PJ; Di Paolo T
    Synapse; 2006 Sep; 60(3):239-50. PubMed ID: 16739115
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chronic treatment with MPEP, an mGlu5 receptor antagonist, normalizes basal ganglia glutamate neurotransmission in L-DOPA-treated parkinsonian monkeys.
    Morin N; Morissette M; Grégoire L; Gomez-Mancilla B; Gasparini F; Di Paolo T
    Neuropharmacology; 2013 Oct; 73():216-31. PubMed ID: 23756168
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined use of the adenosine A(2A) antagonist KW-6002 with L-DOPA or with selective D1 or D2 dopamine agonists increases antiparkinsonian activity but not dyskinesia in MPTP-treated monkeys.
    Kanda T; Jackson MJ; Smith LA; Pearce RK; Nakamura J; Kase H; Kuwana Y; Jenner P
    Exp Neurol; 2000 Apr; 162(2):321-7. PubMed ID: 10739638
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Brain α7 nicotinic acetylcholine receptors in MPTP-lesioned monkeys and parkinsonian patients.
    Morissette M; Morin N; Grégoire L; Rajput A; Rajput AH; Di Paolo T
    Biochem Pharmacol; 2016 Jun; 109():62-69. PubMed ID: 27038656
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Amantadine reduces levodopa-induced dyskinesias in parkinsonian monkeys.
    Blanchet PJ; Konitsiotis S; Chase TN
    Mov Disord; 1998 Sep; 13(5):798-802. PubMed ID: 9756148
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduction of L-DOPA-induced dyskinesia by the selective metabotropic glutamate receptor 5 antagonist 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease.
    Johnston TH; Fox SH; McIldowie MJ; Piggott MJ; Brotchie JM
    J Pharmacol Exp Ther; 2010 Jun; 333(3):865-73. PubMed ID: 20231306
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiparkinsonian actions of CP-101,606, an antagonist of NR2B subunit-containing N-methyl-d-aspartate receptors.
    Steece-Collier K; Chambers LK; Jaw-Tsai SS; Menniti FS; Greenamyre JT
    Exp Neurol; 2000 May; 163(1):239-43. PubMed ID: 10785463
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Translating A2A antagonist KW6002 from animal models to parkinsonian patients.
    Chase TN; Bibbiani F; Bara-Jimenez W; Dimitrova T; Oh-Lee JD
    Neurology; 2003 Dec; 61(11 Suppl 6):S107-11. PubMed ID: 14663022
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of the metabotropic glutamate receptor type 5 antagonists MPEP and MTEP in parkinsonian monkeys.
    Morin N; Grégoire L; Gomez-Mancilla B; Gasparini F; Di Paolo T
    Neuropharmacology; 2010 Jun; 58(7):981-6. PubMed ID: 20074579
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Striatal AMPA receptor binding is unaltered in the MPTP-lesioned macaque model of Parkinson's disease and dyskinesia.
    Silverdale MA; Crossman AR; Brotchie JM
    Exp Neurol; 2002 Mar; 174(1):21-8. PubMed ID: 11869030
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antidyskinetic effect of magnesium sulfate in MPTP-lesioned monkeys.
    Chassain C; Eschalier A; Durif F
    Exp Neurol; 2003 Aug; 182(2):490-6. PubMed ID: 12895461
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quetiapine attenuates levodopa-induced motor complications in rodent and primate parkinsonian models.
    Oh JD; Bibbiani F; Chase TN
    Exp Neurol; 2002 Oct; 177(2):557-64. PubMed ID: 12429201
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term treatment with l-DOPA and an mGlu5 receptor antagonist prevents changes in brain basal ganglia dopamine receptors, their associated signaling proteins and neuropeptides in parkinsonian monkeys.
    Morin N; Jourdain VA; Morissette M; Grégoire L; Di Paolo T
    Neuropharmacology; 2014 Apr; 79():688-706. PubMed ID: 24456747
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.